Gerard Sanacora
Affiliations: | Yale University, New Haven, CT |
Area:
PsychiatryGoogle:
"Gerard Sanacora"Cross-listing: Neurotree
Collaborators
Sign in to add collaborator| Yann Mineur | collaborator | 2005- | Yale (Neurotree) |
| Christopher J. Pittenger | collaborator | 2006- | Yale (Neurotree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Holmes SE, Finnema SJ, Naganawa M, et al. (2022) Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry |
| Averill LA, Averill CL, Gueorguieva R, et al. (2022) mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. Journal of Affective Disorders |
| McIntyre RS, Rosenblat JD, Nemeroff CB, et al. (2021) Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. The American Journal of Psychiatry. appiajp202020081251 |
| Pizzagalli DA, Smoski M, Ang YS, et al. (2020) Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology |
| Pothula S, Kato T, Liu RJ, et al. (2020) Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Molecular Psychiatry |
| Averill LA, Abdallah CG, Fenton LR, et al. (2020) Early life stress and glutamate neurotransmission in major depressive disorder. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology |
| Fu DJ, Ionescu DF, Li X, et al. (2020) Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). The Journal of Clinical Psychiatry. 81 |
| Freeman MP, Hock RS, Papakostas GI, et al. (2020) Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. Journal of Clinical Psychopharmacology. 40: 287-292 |
| Wajs E, Aluisio L, Holder R, et al. (2020) Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). The Journal of Clinical Psychiatry. 81 |
| Krystal AD, Pizzagalli DA, Smoski M, et al. (2020) A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nature Medicine |